

Advocating prudent D-dimer testing: constructive perspectives and comments on ‘How we manage a high D-dimer’

We read with great interest the narrative review, “How we manage a high D-dimer”, authored by Massimo Franchini and colleagues and published in a recent issue of *Haematologica*.¹ This review offers didactic and informative content, and although we generally agree with the perspectives and recommendations presented, we would like to address two specific issues that are vital to good clinical practice: the correct understanding of the properties of diagnostic tests; and the need for reduction of unnecessary test prescription.

Regarding the first issue, the review mentions the intrinsically low positive predictive value (PPV) of D-dimer testing. It is essential to clarify that PPV is not an intrinsic characteristic of the test. Rather, PPV is determined by the interaction between the pre-test probability and the test’s positive likelihood ratio.^{2,3} Therefore, even a test like D-dimer, which has a low positive likelihood ratio,⁴ can exhibit a high PPV if applied in a setting with a very high pre-test probability.

Regarding the second issue, the review highlights that ubiquitous physiological conditions such as aging, pregnancy, and physical activity are among the main causes of elevated D-dimer levels. It also states that D-dimer testing has limited clinical utility in the random asymptomatic ambulatory patient and appropriately suggests that it should only be prescribed in specific clinical situations. Yet, it also asserts that an elevated D-Dimer ordered in the random asymptomatic ambulatory patient cannot be ignored and warrants further consideration and proposes an algorithm for the management of these patients. In our opinion, this approach legitimizes inappropriate ordering of the test and shifts the focus away from what truly should be good clinical practice: the use of a diagnostic test as a complement to sound clinical reasoning. This applies not only to D-dimer, but also to other tests inappropriately routinely ordered in asymptomatic individuals, such as high-sensitivity troponin⁵ and the ANA test.⁶ These tests should be reserved for cases of clinical suspicion due to extremely high false-positive rates in the context of low pre-test probability, which can lead to further unnecessary tests, invasive procedures with iatrogenic risk, increased costs to the healthcare system, and anxiety for the patient. We

reinforce the need for rational patient selection prior to prescribing the diagnostic test, rather than seeking an unlikely diagnosis afterwards motivated by inappropriate test ordering.⁷

For these reasons, we suggest that instead of recommending an evaluation algorithm for elevated D-dimer tests in asymptomatic ambulatory individuals, the focus should shift back towards avoiding unnecessary medical tests. Such efforts could lead to the better education of healthcare professionals on the rational prescription of these tests, ensuring effective and appropriate use based on solid clinical reasoning and a specific patient context.

Authors

Yung Gonzaga^{1,2} and José Nunes de Alencar³

¹Hematology Department, Instituto Nacional de Cancer, Rio de Janeiro; ²Hematology Department, Grupo Oncoclínicas, Rio de Janeiro and ³Cardiology Department, Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil

Correspondence:

Y. GONZAGA - ygonzaga@inca.gov.br

<https://doi.org/10.3324/haematol.2024.285691>

Received: April 17, 2024.

Accepted: May 7, 2024.

Early view: May 16, 2024.

©2024 Ferrata Storti Foundation

Published under a CC BY-NC license 

Disclosures

No conflicts of interest to disclose.

Contributions

YG developed the concept. YG and JNdA wrote the original draft, and reviewed and edited the manuscript.

References

1. Franchini M, Focosi D, Pezzo MP, Mannucci PM. How we manage a high D-dimer. *Haematologica*. 2024;109(4):1035-1045.
2. Akobeng AK. Understanding diagnostic tests 1: sensitivity, specificity and predictive values. *Acta Paediatr*. 2007;96(3):338-341.
3. Akobeng AK. Understanding diagnostic tests 2: likelihood ratios, pre- and post-test probabilities and their use in clinical practice. *Acta Paediatr*. 2007;96(4):487-491.
4. Johnson ED, Schell JC, Rodgers GM. The D-dimer assay. *Am J Hematol*. 2019;94(7):833-839.
5. Brush JE, Kaul S, Krumholz HM. Troponin testing for clinicians. *J Am Coll Cardiol*. 2016;68(21):2365-2375.
6. Kiriakidou M, Ching CL. Systemic Lupus erythematosus. *Ann Intern Med*. 2020;172(11):ITC81-ITC96.
7. de Alencar JN, Santos-Neto L. The post hoc pitfall: rethinking sensitivity and specificity in clinical practice. *J Gen Intern Med*. 2024;39(8):1506-1510